St. George's Respiratory Questionnaire: MCID

The SGRQ is a disease-specific measure of health status for use in COPD. A number of methods have been used for estimating its minimum clinically important difference (MCID). These include both expert and patient preference-based estimates. Anchor-based methods have also been used. The calculated MCID from those studies was consistently around 4 units, regardless of assessment method. By contrast, the MCID calculated using distribution-based methods varied across studies and permitted no consistent estimate. All measurements of clinical significance contain sample and measurement error. They also require value judgements, if not about the calculation of the MCID itself then about the anchors used to estimate it. Under these circumstances, greater weight should be placed upon the overall body of evidence for an MCID, rather than one single method. For that reason, estimates of MCID should be used as indicative values. Methods of analysing clinical trial results should reflect this, and use appropriate statistical tests for comparison with the MCID. Treatments for COPD that produced an improvement in SGRQ of the order of 4 units in clinical trials have subsequently found wide acceptance once in clinical practice, so it seems reasonable to expect any new treatment proposed for COPD to produce an advantage over placebo that is not significantly inferior to a 4-unit difference.

[1]  P. Jones,et al.  Quality of life in patients with chronic obstructive pulmonary disease , 2006 .

[2]  E. Wouters,et al.  Raised CRP levels mark metabolic and functional impairment in advanced COPD , 2005, Thorax.

[3]  T. Gislason,et al.  Risk factors for rehospitalisation in COPD: role of health status, anxiety and depression , 2005, European Respiratory Journal.

[4]  G. Norman,et al.  The truly remarkable universality of half a standard deviation: confirmation through another look , 2004, Expert review of pharmacoeconomics & outcomes research.

[5]  J. Vestbo [Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease]. , 2004, Ugeskrift for laeger.

[6]  P. Calverley,et al.  Maintenance therapy with budesonide and formoterol in chronicobstructive pulmonary disease , 2003, European Respiratory Journal.

[7]  G. Guyatt,et al.  Evaluation of the minimal important difference for the feeling thermometer and the St. George's Respiratory Questionnaire in patients with chronic airflow obstruction. , 2003, Journal of clinical epidemiology.

[8]  H Putter,et al.  Correlation between annual change in health status and computer tomography derived lung density in subjects with α1-antitrypsin deficiency , 2003, Thorax.

[9]  Ruth Etzioni,et al.  Cost effectiveness of lung-volume-reduction surgery for patients with severe emphysema. , 2003, The New England journal of medicine.

[10]  G. Norman,et al.  Interpretation of Changes in Health-related Quality of Life: The Remarkable Universality of Half a Standard Deviation , 2003, Medical care.

[11]  M. Tsukino,et al.  Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. , 2003, American journal of respiratory and critical care medicine.

[12]  R. Pauwels,et al.  Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial , 2003, The Lancet.

[13]  R. Sansores,et al.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease , 2003, European Respiratory Journal.

[14]  Jordi Alonso,et al.  Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[15]  P. Jones Interpreting thresholds for a clinically significant change in health status in asthma and COPD , 2002, European Respiratory Journal.

[16]  M. Ferrer,et al.  Interpretation of quality of life scores from the St George's Respiratory Questionnaire , 2002, European Respiratory Journal.

[17]  R. Zuwallack,et al.  A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[18]  J. V. van Noord,et al.  Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium , 2002, European Respiratory Journal.

[19]  P. Jones,et al.  Health status measurement in chronic obstructive pulmonary disease , 2001, Thorax.

[20]  G. Guyatt,et al.  Relation of Distribution- and Anchor-Based Approaches in Interpretation of Changes in Health-Related Quality of Life , 2001, Medical care.

[21]  R. Dahl,et al.  Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[22]  P M Calverley,et al.  Health status deterioration in patients with chronic obstructive pulmonary disease. , 2001, American journal of respiratory and critical care medicine.

[23]  S. Spencer,et al.  Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial , 2000, BMJ : British Medical Journal.

[24]  N. Payne,et al.  Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial , 2000, The Lancet.

[25]  P. Jones Impact of lower respiratory tract infections on health status. , 2000, Seminars in respiratory and critical care medicine.

[26]  P. Jones,et al.  A comparison of global questions versus health status questionnaires as measures of the severity and impact of asthma. , 1999, The European respiratory journal.

[27]  P. Jones,et al.  Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease , 1999, Thorax.

[28]  P. Jones,et al.  Analysis of factors that characterize health impairment in patients with chronic respiratory failure , 1999 .

[29]  T. Seemungal,et al.  Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. , 1998, American journal of respiratory and critical care medicine.

[30]  M. Tsukino,et al.  Comparison of Discriminative Properties among Disease-specific Questionnaires for Measuring Health-related Quality of Life in Patients with Chronic Obstructive Pulmonary Disease , 1998 .

[31]  P. Jones,et al.  Validation of the St. George's Respiratory Questionnaire in bronchiectasis. , 1997, American journal of respiratory and critical care medicine.

[32]  P. Jones,et al.  Quality of life changes in COPD patients treated with salmeterol. , 1997, American journal of respiratory and critical care medicine.

[33]  J. G. Douglas,et al.  Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. , 1997, Thorax.

[34]  H. R. Anderson,et al.  A computer-assisted telephone interview technique for assessment of asthma morbidity and drug use in adult asthma. , 1996, Journal of clinical epidemiology.

[35]  M. Connolly,et al.  Impact of obstructive airways disease on quality of life in older adults. , 1996, Thorax.

[36]  E. Wouters,et al.  Determinants of health-related quality of life in patients with chronic obstructive pulmonary disease. , 1996, Thorax.

[37]  P. Jones,et al.  Quality of life in patients with chronic obstructive pulmonary disease and severe hypoxaemia. , 1996, Thorax.

[38]  P. Jones,et al.  Quality of life, symptoms and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Nedocromil Sodium Quality of Life Study Group. , 1994, The European respiratory journal.

[39]  P. Jones,et al.  A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. , 1992, The American review of respiratory disease.

[40]  P. Jones,et al.  The St George's Respiratory Questionnaire. , 1991, Respiratory medicine.

[41]  P. Jones,et al.  Influence of demographic and disease related factors on the degree of distress associated with symptoms and restrictions on daily living due to asthma in six countries. , 1991, The European respiratory journal.

[42]  P. Jones,et al.  Patients' perception of distress due to symptoms and effects of asthma on daily living and an investigation of possible influential factors. , 1990, Clinical science.

[43]  G. Guyatt,et al.  Measurement of health status. Ascertaining the minimal clinically important difference. , 1989, Controlled clinical trials.